Revance Therapeutics Stock Forecast, Price & News

Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

Is Revance Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Revance Therapeutics stock.
View analyst ratings for Revance Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Revance Therapeutics?

Wall Street analysts have given Revance Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Revance Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Revance Therapeutics.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.07. The biopharmaceutical company earned $18.80 million during the quarter, compared to the consensus estimate of $16.68 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 103.06% and a negative net margin of 644.56%.
View Revance Therapeutics' earnings history.

How has Revance Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RVNC shares have decreased by 21.1% and is now trading at $14.1750.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for RVNC?

5 analysts have issued 12-month price targets for Revance Therapeutics' stock. Their forecasts range from $17.00 to $36.00. On average, they expect Revance Therapeutics' share price to reach $27.40 in the next twelve months. This suggests a possible upside of 93.3% from the stock's current price.
View analysts' price targets for Revance Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the following people:

• Mark J. Foley, President, Chief Executive Officer & Director
• Abhay Joshi, COO & President-Research & Development
• Tobin C. Schilke, Chief Financial Officer
• Azita Nejad, Senior Vice President-Technical Operations
• Roman G. Rubio, Senior Vice President-Clinical Development

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics CEO Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among Revance Therapeutics' employees.

Who are some of Revance Therapeutics' key competitors?

Some companies that are related to Revance Therapeutics include Karuna Therapeutics (KRTX), Schrödinger (SDGR), Aurinia Pharmaceuticals (AUPH), Cryoport (CYRX), Arena Pharmaceuticals (ARNA), Reata Pharmaceuticals (RETA), Zentalis Pharmaceuticals (ZNTL), Intra-Cellular Therapies (ITCI), Lyell Immunopharma (LYEL), Galapagos (GLPG), Hypera (HYPMY), Insmed (INSM), Cytokinetics (CYTK), Prestige Consumer Healthcare (PBH) and Nektar Therapeutics (NKTR).
View all of RVNC's competitors.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Genesee Capital Advisors LLC (0.10%) and Carnegie Capital Asset Management LLC (0.01%). Company insiders that own Revance Therapeutics stock include Aubrey Rankin and Dwight Moxie.
View institutional ownership trends for Revance Therapeutics.

Which major investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC. Company insiders that have sold Revance Therapeutics company stock in the last year include Aubrey Rankin, and Dwight Moxie.
View insider buying and selling activity for Revance Therapeutics or view top insider-selling stocks.

Which major investors are buying Revance Therapeutics stock?

RVNC stock was acquired by a variety of institutional investors in the last quarter, including Genesee Capital Advisors LLC.
View insider buying and selling activity for Revance Therapeutics or or view top insider-buying stocks.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $14.18.

How much money does Revance Therapeutics make?

Revance Therapeutics has a market capitalization of $1.02 billion and generates $15.32 million in revenue each year. The biopharmaceutical company earns $-282.09 million in net income (profit) each year or ($4.86) on an earnings per share basis.

How many employees does Revance Therapeutics have?

Revance Therapeutics employs 470 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is www.revance.com.

Where are Revance Therapeutics' headquarters?

Revance Therapeutics is headquartered at 7555 GATEWAY BLVD., NEWARK CA, 94560.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at (615) 724-7755 or via email at [email protected].